1AI algorae pharmaceuticals limited

Ann: Half Yearly Report and Accounts, page-5

  1. 13,565 Posts.
    lightbulb Created with Sketch. 7330
    INCORRECT NEWS ,Annoyed at the very least. report states LCT loss is 42c per share
    Column 1
    0 Living Cell Technologies reports wider 1H lossThursday, 23 February 2017, 8:49 amArticle: BusinessDesk
    Wednesday 22 February 2017 03:02 PM
    Living Cell Technologies reports wider 1H loss
    By Rebecca Howard
    Feb. 22 (BusinessDesk) - Living Cell Technologies, the ASX-listed biotech company with New Zealand-based operations, reported a wider loss in the six months to Dec 31 on increased research and development.
    The company said its consolidated operating loss after tax was A$2.1 million versus a loss of A$1.4 million in the same period a year earlier. Its loss per share was 42 Australian cents versus a loss of 34 Australian cents a year earlier. The main reason was increased costs incurred during the clinical trial of Living Cell's NTCELL product to treat Parkinson's disease, as well as the cost of security the supply and manufacture of NTCELL, the company said. Earlier this month it received approval to begin treating six patients in group 3 of the trial at Auckland City Hospital.
    This could explain the sharp sell down when we are only days away from completing Phase II trials.
    Have informed LCT Public Relations.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.5¢
Change
0.000(0.00%)
Mkt cap ! $8.436M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $346 69.12K

Buyers (Bids)

No. Vol. Price($)
9 2490418 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 3429885 6
View Market Depth
Last trade - 12.09pm 04/07/2025 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.